Comparing Ahmed-FP7 to Baerveldt-250 and Baerveldt-350 surgical outcomes: 1-year results from a retrospective cohort study leveraging the electronic health record.
Comparing Ahmed-FP7 to Baerveldt-250 and Baerveldt-350 surgical outcomes: 1-year results from a retrospective cohort study leveraging the electronic health record.
复制标题
DOI：
10.1136/bmjophth-2023-001308
复制
发表时间：
2023-06
影响因子：
2.4
通讯作者：
中科院分区：
文献类型：
--
作者：
比较 Ahmed-FP7 (AGI-FP7)、Baerveldt-250mm2 (BGI-250) 或 Baerveldt-350mm2 (BGI-350) 植入后的结果。回顾性队列研究包括 2016 年 1 月 1 日至 2020 年 12 月 31 日在三级医疗机构接受手术的 800 人的 800 只眼睛。数据是从电子健康记录中的标准化字段中提取的。主要结局为失败（定义为从第 3 个月起连续两次就诊时眼压 (IOP) ≤5mm Hg 或 >18mm Hg 或降低 <20%；或视力 (VA) 损失≥3 行；或返回手术室 (OR)）。次要结局是 IOP、VA、随访次数和返回手术室的次数。总共分析了 523 个 AGI-FP7、133 个 BGI-250 和 144 个 BGI-350 病例。 AGI-FP7 组更年轻并被诊断为继发性青光眼，平均基线 IOP 较高（BGI-250 中为 28.5±12.2 毫米汞柱 vs 22.0±7.7mm Hg，BGI-350 中为 23.4±9.0 毫米汞柱，p<0.001）。第 12 个月的累积失败率为 30% (AGI-FP7) vs 39% (BGI-250) vs 33% (BGI-350，p=0.159)。与 AGI-FP7 组相比，BGI-350 组第 12 个月时的平均 IOP 较低（12.4±4.4 vs 14.8±5.6mm Hg，p=0.003），但 BGI-250 组则不然（vs 13.1±4.6，p=0.710）。 71% 的 AGI-FP7、66% BGI-250 和 76% BGI-350 实现了目标眼压。 VA 损失和手术室返回率在各组之间没有差异。 BGI-250 和 BGI-350 的随访次数均多于 AGI-FP7 (p<0.001)。这三种青光眼引流装置在 1 年内表现相似，尽管患者基线特征不同，但故障率没有差异。
To compare outcomes following Ahmed-FP7 (AGI-FP7), Baerveldt-250mm2 (BGI-250), or Baerveldt-350mm2 (BGI-350) implantation. Retrospective cohort study comprising 800 eyes from 800 individuals who underwent surgery 1 January 2016–31 December 2020 at a tertiary-care institution. Data were extracted from standardised fields in the electronic health record. Primary outcome was failure (defined as intraocular pressure (IOP) ≤5 mm Hg or >18 mm Hg or reduction <20% at two consecutive visits from month 3 onwards; or visual acuity (VA) loss ≥3 lines; or return to the operating room (OR)). Secondary outcomes were IOP, VA, number of follow-up visits and return to the OR. A total of 523 AGI-FP7, 133 BGI-250 and 144 BGI-350 cases were analysed. The AGI-FP7 group was more likely to be younger and diagnosed with secondary glaucoma, with a higher mean baseline IOP (28.5±12.2 vs 22.0±7.7 mm Hg in BGI-250 and 23.4±9.0 in BGI-350, p<0.001). Cumulative failure rate at month 12 was 30% (AGI-FP7) vs 39% (BGI-250) vs 33% (BGI-350, p=0.159). Mean IOP at month 12 was lower in the BGI-350 group compared with AGI-FP7 (12.4±4.4 vs 14.8±5.6 mm Hg, p=0.003) but not BGI-250 (vs 13.1±4.6, p=0.710). Target IOP was achieved in 71% of AGI-FP7, 66% BGI-250, and 76% BGI-350. VA loss and rates of return to the OR did not differ between groups. Both BGI-250 and BGI-350 had more follow-up visits than AGI-FP7 (p<0.001). These three glaucoma drainage devices performed similarly within 1 year, with no difference in failure rates despite differing baseline patient characteristics.